{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:55:25Z","timestamp":1773284125595,"version":"3.50.1"},"reference-count":91,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1097\/mjt.0b013e318245992d","type":"journal-article","created":{"date-parts":[[2012,9,18]],"date-time":"2012-09-18T09:08:39Z","timestamp":1347959319000},"page":"385-394","source":"Crossref","is-referenced-by-count":8,"title":["Clostridium Difficile Colitis"],"prefix":"10.1097","volume":"21","author":[{"given":"Josmi","family":"Joseph","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shashideep","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gia M.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sury","family":"Anand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-10-20210202","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1099\/jmm.0.030015-0","article-title":"The host immune response to Clostridium difficile.","volume":"60","author":"Kelly","year":"2011","journal-title":"J Med Microbiol"},{"key":"R2-10-20210202","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1086\/338260","article-title":". Healthcare costs and mortality associated with healthcare-associated diarrhea due to Clostridium difficile.","volume":"34","author":"Kyne","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R3-10-20210202","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1038\/ajg.2010.254","article-title":". Prevention of endemic healthcare-associated Clostridium difficile infection: reviewing the evidence.","volume":"105","author":"Hsu","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R4-10-20210202","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa051639","article-title":". A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality.","volume":"353","author":"Loo","year":"2005","journal-title":"N Engl J Med"},{"key":"R5-10-20210202","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1086\/501126","article-title":". Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada.","volume":"42","author":"Pepin","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R6-10-20210202","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1503\/cmaj.1041104","article-title":". Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity.","volume":"171","author":"Pepin","year":"2004","journal-title":"CMAJ"},{"key":"R7-10-20210202","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/qjmed\/hch076","article-title":". Antibiotic prescribing policy and Clostridium difficile diarrhea.","volume":"97","author":"OConnor","year":"2004","journal-title":"QJM"},{"key":"R8-10-20210202","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1128\/AAC.35.1.208","article-title":". Prospective study of Clostridium difficile intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery.","volume":"35","author":"Privitera","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"R9-10-20210202","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1038\/ajg.2010.142","article-title":"Glucocorticoids are associated with increased risk of short-term mortality in hospitalized patients with Clostridium difficile-associated disease.","volume":"105","author":"Das","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R10-10-20210202","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nrgastro.2010.190","article-title":"Clostridium difficile infection: epidemiology, riskfactors and management.","volume":"8","author":"Ananthakrishnan","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R11-10-20210202","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.3748\/wjg.v16.i28.3573","article-title":". Protonpump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea.","volume":"16","author":"Kim","year":"2010","journal-title":"World J Gastroenterol"},{"key":"R12-10-20210202","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/BF02710173","article-title":". pseudomembranouscolitis associated with chemotherapy with 5-fluorouracil.","volume":"7","author":"Morales Chamorro","year":"2005","journal-title":"Clin Transl Oncol"},{"key":"R13-10-20210202","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1086\/322616","article-title":". Clostridium difficile infection in patients with neutropenia.","volume":"33","author":"Gorschluter","year":"2001","journal-title":"Clin Infect Dis"},{"key":"R14-10-20210202","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S0140-6736(78)92151-7","article-title":". Diarrhoea and pseudomembranous colitis after gastrointestinal operations: a prospective study.","volume":"2","author":"Keighley","year":"1978","journal-title":"Lancet"},{"key":"R15-10-20210202","doi-asserted-by":"crossref","first-page":"289","DOI":"10.4103\/0255-0857.55436","article-title":"Established and potential risk factors for Clostridum difficile infection.","volume":"27","author":"Vaishnavi","year":"2009","journal-title":"Indian J Med Microbiol"},{"key":"R16-10-20210202","first-page":"867","article-title":"Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis.","volume":"80","author":"Tedesco","year":"1985","journal-title":"Am J Gastroenterol"},{"issue":"suppl 1","key":"R17-10-20210202","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1086\/521863","article-title":"Clinical recognition and diagnosis of Clostridium difficile infection.","volume":"46","author":"Bartlett","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R18-10-20210202","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1469-0691.2009.02713.x","article-title":". Successful combat of an outbreak due to Clostridium difficile PCr ribotype 027 and recognition of specific risk factors.","volume":"15","author":"Debast","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"R19-10-20210202","doi-asserted-by":"crossref","first-page":"632","DOI":"10.7326\/0003-4819-148-8-200804150-00024","article-title":"Successful treatment of fulminant Clostridium difficile infection with fecal bacteriotherapy.","volume":"148","author":"You","year":"2008","journal-title":"Ann Intern Med"},{"key":"R20-10-20210202","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1086\/502278","article-title":". Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years.","volume":"24","author":"Carling","year":"2003","journal-title":"Infect Control Hosp Epidemiol"},{"key":"R21-10-20210202","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1469-0691.2006.01634.x","article-title":". Isolation and characterisation of toxin A-negative, toxin B-positive Clostridium difficile in Dublin, Ireland.","volume":"13","author":"Drudy","year":"2007","journal-title":"Clin Microbiol Infect"},{"key":"R22-10-20210202","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3393\/jksc.2010.26.5.329","article-title":". Risk factors for the development of Clostridium difficile-associated colitis after colorectal cancer surgery.","volume":"26","author":"Yeom","year":"2010","journal-title":"J Korean Soc Coloproctology"},{"key":"R23-10-20210202","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/ageing\/28.2.107","article-title":". Factors associated with prolonged symptoms and severe disease due to Clostridium difficile.","volume":"28","author":"Kyne","year":"1999","journal-title":"Age Ageing"},{"key":"R24-10-20210202","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1086\/651706","article-title":"; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).","volume":"31","author":"Cohen","year":"2010","journal-title":"Infect Control Hosp Epidemiol"},{"key":"R25-10-20210202","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/IPC.0b013e318182557f","article-title":". A severity score index for Clostridium difficile infection.","volume":"16","author":"Velazquez-Gomez","year":"2008","journal-title":"Infect Dis Clin Pract"},{"key":"R26-10-20210202","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00003088-199936050-00004","article-title":". Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials.","volume":"36","author":"Lamp","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"R27-10-20210202","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.cgh.2008.06.024","article-title":". A prospective study of risk factorsand historical trends in metronidazole failure for Clostridium difficile infection.","volume":"6","author":"Hu","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R28-10-20210202","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1086\/430311","article-title":". Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole.","volume":"40","author":"Musher","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R29-10-20210202","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2165\/00003088-198611040-00001","article-title":"Clinical pharmacokinetics of vancomycin.","volume":"11","author":"Matzke","year":"1986","journal-title":"Clin Pharmacokinet"},{"key":"R30-10-20210202","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1086\/519265","article-title":". A comparison of vancomycin and metronidazole for the treatment of Clostridiumdifficile-associated diarrhea, stratified bydisease severity.","volume":"45","author":"Zar","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R31-10-20210202","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1111\/j.1572-0241.2007.01539.x","article-title":". Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP 1027.","volume":"102","author":"Pepin","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R32-10-20210202","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0002-9343(89)90223-4","article-title":". Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens.","volume":"86","author":"Fekety","year":"1989","journal-title":"Am J Med"},{"key":"R34-10-20210202","first-page":"83","article-title":". Evaluation of metronidazole toxicity: a prospective study.","volume":"19","author":"Kapoor","year":"1999","journal-title":"Int J Clin Pharmacol Res"},{"key":"R35-10-20210202","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1128\/JCM.38.6.2386-2388.2000","article-title":". Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea.","volume":"38","author":"Barbut","year":"2000","journal-title":"J Clin Microbiol"},{"key":"R36-10-20210202","first-page":"93","article-title":"Settle CD, et al..","volume":"38","author":"Wilcox","year":"1998","journal-title":"Recurrence of symptoms in Clostridium difficile infectionrelapse or reinfection J Hosp Infect"},{"key":"R37-10-20210202","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1111\/j.1572-0241.2002.05839.x","article-title":"Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease.","volume":"97","author":"McFarland","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R38-10-20210202","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jinf.2009.03.010","article-title":"Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes.","volume":"58","author":"Johnson","year":"2009","journal-title":"J Infect"},{"key":"R39-10-20210202","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1128\/AAC.48.6.2280-2282.2004","article-title":". In vitro activity of OPT-80 against Clostridium difficile.","volume":"48","author":"Ackermann","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R40-10-20210202","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1128\/AAC.48.12.4898-4902.2004","article-title":". In vitro activities of OPT-80 and comparator drugs against intestinal bacteria.","volume":"48","author":"Finegold","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R41-10-20210202","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1128\/AAC.01623-06","article-title":". In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004.","volume":"51","author":"Hecht","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R42-10-20210202","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":". Fidaxomicin versus vancomycin for Clostridium difficile infection. OPT-80-003 Clinical Study Group.","volume":"364","author":"Louie","year":"2011","journal-title":"N Engl J Med"},{"key":"R43-10-20210202","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1586\/egh.09.63","article-title":"Rifaximin in the management of colonic diverticular disease.","volume":"3","author":"Latella","year":"2009","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R44-10-20210202","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/1756283X10372985","article-title":". Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial.","volume":"3","author":"Patrick Basu","year":"2010","journal-title":"Therap Adv Gastroenterol"},{"key":"R45-10-20210202","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1086\/511870","article-title":". Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin.","volume":"44","author":"Johnson","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R46-10-20210202","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.anaerobe.2009.08.004","article-title":". Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment.","volume":"15","author":"Johnson","year":"2009","journal-title":"Anaerobe"},{"key":"R47-10-20210202","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1345\/aph.1E397","article-title":"Ramoplanin: a lipoglycodepsipeptide antibiotic.","volume":"39","author":"Farver","year":"2005","journal-title":"Ann Pharmacother"},{"key":"R48-10-20210202","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1128\/AAC.49.3.1157-1159.2005","article-title":". In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole.","volume":"49","author":"Pelaez","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"R50-10-20210202","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1586\/14787210.4.6.939","article-title":"Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent.","volume":"4","author":"Fulco","year":"2006","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R51-10-20210202","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1086\/506351","article-title":". Nitazoxanide for the treatment of Clostridium difficile colitis.","volume":"43","author":"Musher","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R52-10-20210202","doi-asserted-by":"crossref","first-page":"E41","DOI":"10.1086\/596552","article-title":". Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study.","volume":"48","author":"Musher","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R53-10-20210202","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/jac\/dkl553","article-title":". Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide.","volume":"59","author":"Musher","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"R54-10-20210202","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1007\/s10620-007-9957-3","article-title":". Fucoidin prevents Clostridium difficile toxin-A-induced ileal enteritis in mice.","volume":"53","author":"Barreto","year":"2008","journal-title":"Dig Dis Sci"},{"key":"R55-10-20210202","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000104471","article-title":"Pharmacodynamic studies of vancomycin, metronidazole and fusidic acid against Clostridium difficile.","volume":"53","author":"Odenholt","year":"2007","journal-title":"Chemotherapy"},{"key":"R56-10-20210202","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/BF01645961","article-title":"Fusidic acid for the treatment of antibiotic-associated colitis induced by Clostridium difficile.","volume":"12","author":"Cronberg","year":"1984","journal-title":"Infection"},{"key":"R57-10-20210202","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3109\/00365549409011800","article-title":"Treatment of Clostridium difficile associated diarrhea and colitis with an oral preparation of teicoplanin: a dose finding study.","volume":"26","author":"Wistrom","year":"1994","journal-title":"Scand J Infect Dis"},{"issue":"3","key":"R58-10-20210202","first-page":"CD004610","article-title":"Antibiotic treatment for Clostridium difficile-associated diarrhea in adults.","author":"Nelson","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"R59-10-20210202","doi-asserted-by":"crossref","first-page":"949","DOI":"10.2147\/TCRM.S3145","article-title":". New advances in the treatment of Clostridium difficile infection (CDI).","volume":"4","author":"Hedge","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"R60-10-20210202","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/00043426-199211000-00015","article-title":"Multiple relapses of Clostridium difficile-associated diarrhea in a cancer patient.","volume":"14","author":"Moncino","year":"1992","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"R61-10-20210202","first-page":"1049","article-title":"The role of anion-exchange resins in the treatment of antibiotic-associated pseudomembranous colitis.","volume":"142","author":"Ariano","year":"1990","journal-title":"CMAJ"},{"key":"R62-10-20210202","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/bjs.1800690306","article-title":". Randomized controlled trial of colestipol in antibiotic-associated colitis.","volume":"69","author":"Mogg","year":"1982","journal-title":"Br J Surg"},{"key":"R63-10-20210202","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1529\/biophysj.104.041277","article-title":". Toxin binding of tolevamer, a polyanionic drug that protects against antibiotic-associated diarrhea.","volume":"87","author":"Braunlin","year":"2004","journal-title":"Biophys J"},{"key":"R64-10-20210202","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1128\/AAC.45.8.2340-2347.2001","article-title":". GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis.","volume":"45","author":"Kurtz","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"R65-10-20210202","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1086\/506349","article-title":". Tolevamer Study Investigator Group. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea.","volume":"43","author":"Louie","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R66-10-20210202","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1128\/AAC.01085-08","article-title":"Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection.","volume":"53","author":"Baines","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R67-10-20210202","doi-asserted-by":"crossref","first-page":"6339","DOI":"10.1128\/IAI.00982-06","article-title":". Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters.","volume":"74","author":"Babcock","year":"2006","journal-title":"Infect Immun"},{"key":"R68-10-20210202","first-page":"1445","article-title":"Treatment with monoclonal antibodies against Clostridium difficile toxins.","volume":"362","author":"Dawson","year":"2010","journal-title":"N Engl J Med"},{"key":"R69-10-20210202","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1056\/NEJMoa0907635","article-title":". Treatment with monoclonal antibodies against Clostridium difficile toxins.","volume":"362","author":"Lowy","year":"2010","journal-title":"N Engl J Med"},{"key":"R70-10-20210202","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1086\/496986","article-title":". Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.","volume":"41","author":"Pepin","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R72-10-20210202","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/jac\/dkr027","article-title":". Evidence of intravenous immunoglobulin as a critical supportive therapy against Clostridium difficile toxin-mediated lethality in mice.","volume":"66","author":"Saito","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"R73-10-20210202","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/jhm.542","article-title":". Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of the literature.","volume":"5","author":"Abougergi","year":"2010","journal-title":"J Hosp Med"},{"key":"R74-10-20210202","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1099\/00222615-47-10-879","article-title":"Binding of Clostridium difficile toxin A to human milk secretory component.","volume":"47","author":"Dallas","year":"1998","journal-title":"J Med Microbiol"},{"key":"R75-10-20210202","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijantimicag.2008.07.011","article-title":"Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer.","volume":"33","author":"Weiss","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"R76-10-20210202","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1128\/AAC.41.2.236","article-title":". Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract.","volume":"41","author":"Kelly","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"R77-10-20210202","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1128\/AAC.00476-08","article-title":"In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile.","volume":"52","author":"Karlowsky","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R78-10-20210202","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1128\/AAC.01143-07","article-title":". Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters.","volume":"52","author":"Kokkotou","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R79-10-20210202","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/jac\/46.4.603","article-title":"Effect of supplements with lactic acid bacteria and oligofructose on the intestinal microflora during administration of cefpodoxime proxetil.","volume":"46","author":"Orrhage","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"R80-10-20210202","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1128\/AEM.69.4.1920-1927.2003","article-title":"Nondigestible oligosaccharides enhance bacterial colonization resistance against Clostridium difficile in vitro.","volume":"69","author":"Hopkins","year":"2003","journal-title":"Appl Environ Microbiol"},{"key":"R81-10-20210202","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1128\/JCM.30.7.1837-1840.1992","article-title":". Comparison of the VIDAS Clostridium difficile toxin A immunoassay with C. difficile culture and cytotoxin and latex tests.","volume":"30","author":"Shanholtzer","year":"1992","journal-title":"J Clin Microbiol"},{"key":"R82-10-20210202","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.cell.2004.07.002","article-title":". Recognition of ommensal microflora by toll-like receptors is required for intestinal homeostasis.","volume":"118","author":"Rakoff-Nahoum","year":"2004","journal-title":"Cell"},{"key":"R83-10-20210202","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S1521-6918(03)00074-X","article-title":"Probiotics to enhance anti-infective defences in the gastrointestinal tract.","volume":"17","author":"Gill","year":"2003","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"R84-10-20210202","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/01.mcg.0000128988.13808.dc","article-title":". Bacteriotherapy using fecal flora: toying with human motions.","volume":"38","author":"Borody","year":"2004","journal-title":"J Clin Gastroenterol"},{"key":"R85-10-20210202","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/jac\/dkf194","article-title":"Probiotics in human infections.","volume":"50","author":"Sullivan","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"R86-10-20210202","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1086\/430315","article-title":". Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada.","volume":"40","author":"Pepin","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R87-10-20210202","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cgh.2010.01.007","article-title":"Success of self-administered home fecal transplantation for chronic Clostridium difficile infection.","volume":"8","author":"Silverman","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R88-10-20210202","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/MOG.0b013e32831da7c4","article-title":"Renewed interest in a difficult disease: Clostridium difficile infectionsepidemiology and current treatment strategies.","volume":"25","author":"McFarland","year":"2009","journal-title":"Curr Opin Gastroenterol"},{"key":"R89-10-20210202","first-page":"178","article-title":"Pseudomembraneous enterocolitis: mechanism for restoring floral homeostasis.","volume":"47","author":"Bowden","year":"1981","journal-title":"Am Surg"},{"key":"R90-10-20210202","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.sla.0000236628.79550.e5","article-title":". Impact of emergency colectomy on survival in patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain.","volume":"245","author":"Lamontagne","year":"2007","journal-title":"Ann Surg"},{"key":"R92-10-20210202","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3201\/eid1205.051064","article-title":"Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003.","volume":"12","author":"McDonald","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"R93-10-20210202","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/ajg.2009.615","article-title":". Clostridium difficile is associated with poor outcomes in patients with cirrhosis: a national and tertiary center perspective.","volume":"105","author":"Bajaj","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R94-10-20210202","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/145749691009900209","article-title":"Clostridium difficile colitis: a call for aggressive management.","volume":"99","author":"Grewal","year":"2010","journal-title":"Scand J Surg"},{"key":"R95-10-20210202","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1463-1318.2005.00876.x","article-title":". The outcome of surgery in fulminant Clostridium difficile colitis.","volume":"8","author":"Koss","year":"2006","journal-title":"Colorectal Dis"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00045391-201409000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T06:42:36Z","timestamp":1618036956000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-201409000-00010"}},"subtitle":["Review of the Therapeutic Approach"],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":91,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e318245992d","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]}}}